Christopher Kachulis

Christopher Kachulis

Auto-generated profile, based on publicly available information

Christopher Kachulis

Scalable Services, Broad Institute of MIT and Harvard, 415 Main St, Cambridge, MA 02142, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2024 in Nature Medicine
Verified
Journal Article
Open access
PDF file
NLNiall J. Lennon
Niall J. Lennon
LKLeah C. Kottyan
Leah C. Kottyan
CKChristopher Kachulis
Christopher Kachulis
Noura Abul-HusnNoura Abul-Husn
Noura Abul-Husn
JAJosh Arias
Josh Arias
EKEimear E. Kenny
Eimear E. Kenny
Polygenic risk scores (PRSs) have improved in predictive performance, but several challenges remain to be addressed before PRSs can be implemented in the clinic, including reduced predictive performance of PRSs in diverse populations, and the interpretation and communication of genetic results to both providers and patients. To address these challenges, the National Human Genome Research Institute-funded Electronic Medical Records and Genomics (eMERGE) Network has developed a framework and pipeline for return of a PRS-based genome-informed risk assessment to 25,000 diverse adults and children as part of a clinical study. From an initial list of 23 conditions, ten were selected for implementation based on PRS performance, medical actionability and potential clinical utility, including cardiometabolic diseases and cancer. Standardized metrics were considered in the selection process, with additional consideration given to strength of evidence in African and Hispanic populations. We then developed a pipeline for clinical PRS implementation (score transfer to a clinical laboratory, validation and verification of score performance), and used genetic ancestry to calibrate PRS mean and variance, utilizing genetically diverse data from 13,475 participants of the All of Us Research Program cohort to train and test model parameters. Finally, we created a framework for regulatory compliance and developed a PRS clinical report for return to providers and for inclusion in an additional genome-informed risk assessment. The initial experience from eMERGE can inform the approach needed to implement PRS-based testing in diverse clinical settings.

9 September 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
TBToni A Boltz
Toni A Boltz
BCBenjamin B Chu
Benjamin B Chu
CLCalwing Liao
Calwing Liao
JSJulia M Sealock
Julia M Sealock
RYRobert Ye
Robert Ye
AMALICIA MARTIN
ALICIA MARTIN
We deployed the Blended Genome Exome (BGE), a DNA library blending approach that generates low pass whole genome (1-4x mean depth) and deep whole exome (30-40x mean depth) data in a single sequencing run. This technology is cost-effective, empowers most genomic discoveries possible with deep whole genome sequencing, and provides an unbiased method to capture the diversity of common SNP variation across the globe. To evaluate this new technology at scale, we applied BGE to sequence >53,000 samples from the Populations Underrepresented in Mental Illness Associations Studies (PUMAS) Project, which included participants across African, African American, and Latin American populations. We evaluated the accuracy of BGE imputed genotypes against raw genotype calls from the Illumina Global Screening Array. All PUMAS cohorts had R 2 concordance ≥95% among SNPs with MAF≥1%, and never fell below ≥90% R 2 for SNPs with MAF<1%. Furthermore, concordance rates among local ancestries within two recently admixed cohorts were consistent among SNPs with MAF≥1%, with only minor deviations in SNPs with MAF<1%. We also benchmarked the discovery capacity of BGE to access protein-coding copy number variants (CNVs) against deep whole genome data, finding that deletions and duplications spanning at least 3 exons had a positive predicted value of ∼90%. Our results demonstrate BGE scalability and efficacy in capturing SNPs, indels, and CNVs in the human genome at 28% of the cost of deep whole-genome sequencing. BGE is poised to enhance access to genomic testing and empower genomic discoveries, particularly in underrepresented populations.

26 January 2026 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
JVJason Vassy
Jason Vassy
ADAnna M. Dornisch
Anna M. Dornisch
RKRoshan Karunamuni
Roshan Karunamuni
MGMichael Gatzen
Michael Gatzen
CKChristopher J. Kachulis
Christopher J. Kachulis
TSTyler M. Seibert
Tyler M. Seibert

1 February 2024 in JCO Precision Oncology
Verified
Journal Article
Closed access
TSTakuto Sato
Takuto Sato
KMKamaneh Montazeri
Kamaneh Montazeri
EGEvangelos S. Gragoudas
Evangelos S. Gragoudas
ALAnne Marie Lane
Anne Marie Lane
MAMary Beth Aronow
Mary Beth Aronow
IKIvana K Kim
Ivana K Kim
PURPOSE: Somatic chromosomal alterations, particularly monosomy 3 and 8q gains, have been associated with metastatic risk in uveal melanoma (UM). Whole genome-scale evaluation of detectable alterations in cell-free DNA (cfDNA) in UM could provide valuable prognostic information. Our pilot study evaluates the correlation between genomic information using ultra-low-pass whole-genome sequencing (ULP-WGS) of cfDNA in UM and associated clinical outcomes. MATERIALS AND METHODS: ULP-WGS of cfDNA was performed on 29 plasma samples from 16 patients, 14 metastatic UM (mUM) and two non-metastatic, including pre- and post-treatment mUM samples from 10 patients treated with immunotherapy and one with liver-directed therapy. We estimated tumor fraction (TFx) and detected copy-number alterations (CNAs) using ichorCNA. Presence of 8q amplification was further analyzed using the likelihood ratio test (LRT). RESULTS: Eleven patients with mUM (17 samples) of 14 had detectable circulating tumor DNA (ctDNA). 8q gain was detected in all 17, whereas monosomy 3 was detectable in 10 of 17 samples. TFx generally correlated with disease status, showing an increase at the time of disease progression (PD). 8q gain detection sensitivity appeared greater with the LRT than with ichorCNA at lower TFxs. The only patient with mUM with partial response on treatment had a high pretreatment TFx and undetectable on-treatment ctDNA, correlating with her profound response and durable survival. CONCLUSION: ctDNA can be detected in mUM using ULP-WGS, and the TFx correlates with DS. 8q gain was consistently detectable in mUM, in line with previous studies indicating 8q gains early in primary UM and higher amplification with PD. Our work suggests that detection of CNAs by ULP-WGS, particularly focusing on 8q gain, could be a valuable blood biomarker to monitor PD in UM.

8 July 2026 in Nature Genetics
Verified
Journal Article
Open access
PDF file
TBToni A Boltz
Toni A Boltz
BCBenjamin B Chu
Benjamin B Chu
MDMatthew DeFelice
Matthew DeFelice
CLCalwing Liao
Calwing Liao
JSJulia M Sealock
Julia M Sealock
AMALICIA MARTIN
ALICIA MARTIN
Here we developed and deployed the blended genome exome (BGE) method, a DNA library approach that generates low-pass whole-genome (1–4× mean depth) and deep whole-exome (30–40× mean depth) data in a single sequencing run. BGE is cost-effective, empowers most genomic discoveries possible with deep whole-genome sequencing and captures global common single-nucleotide polymorphism diversity. We applied BGE to sequence >53,000 samples from the PUMAS Project (Populations Underrepresented in Mental Illness Associations Studies), including African, African American and Latin American populations. Imputed genotypes showed high concordance with Illumina Global Screening Array calls ( R 2 ≥ 95% for minor allele frequency ≥1%; ≥90% for minor allele frequency <1%), with consistent performance across local ancestries in admixed cohorts. For protein-coding copy number variants, deletions and duplications spanning at least three exons had a positive predicted value of ~90% relative to deep whole-genome data. At ~28% of the cost of deep whole-genome sequencing, BGE provides a scalable, reliable platform to expand genomic discovery and equitable access to sequencing in underrepresented populations.

31 August 2026 in medRxiv
Verified
Preprint
Open access
PDF file
FIFranjo Ivankovic
Franjo Ivankovic
AKArthur Ko
Arthur Ko
MAM. Morgan Aster
M. Morgan Aster
MBMary K Balaconis
Mary K Balaconis
EBEric Banks
Eric Banks
LLLee T Lichtenstein
Lee T Lichtenstein
Summary: Genotype imputation remains essential for large-scale human genetics studies, but its performance is limited by the size and ancestral diversity of available reference panels, reducing accuracy for rare variants and underrepresented populations. Here, we present a cloud-based imputation service built on a multi-ancestry reference panel derived from 515,579 jointly phased genomes from the All of Us (N=414,830) and National Human Genome Research Institute’s Analysis, Visualization, and Informatics Lab-space (AnVIL, N=100,749) datasets. The All of Us + AnVIL reference panel is highly diverse and includes 261,163 participants most genetically similar to non-European reference populations, spanning 665,398,839 high-quality autosomal sites, representing a nearly 50% increase over TOPMed, the previous largest imputation service. Across multiple ancestry groups, the panel enables accurate imputation (empirical R² > 0.8) for variants with allele frequencies as low as 0.2%, extending reliable imputation into the rare-variant frequency spectrum, including allele frequencies down to 0.002% and 0.006% for samples with European ancestry and African ancestry in the United States, respectively. Compared with TOPMed, the panel improves imputation accuracy across all ancestry groups except Africans, and recovers additional trait-associated variants not represented in existing reference panels. To facilitate broad community access while preserving participant privacy, we deploy the panel through a secure cloud-based imputation platform using privacy-preserving recombined haplotypes. This resource establishes a new foundation for genome-wide association studies (GWAS) and fine-mapping, especially in previously underrepresented populations.